Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
(NASDAQ: RCKT) Delayed: 3.56 +0.10 (2.89%)
Previous Close $3.46    52 Week High $ 
Open $3.40    52 Week Low $ 
Day High $3.59    P/E N/A 
Day Low $3.39    EPS $ 
Volume 483,796